Showing results (11-20 of 92) with videos related to
Sort By:
Pageof 10
Hybridoma (2005)|June 29, 2011
Diagnostic and possible therapeutic application of a monoclonal antibody (14G8) directed against botulinum type C neurotoxinVicki A Montgomery, Leonard A SmithExpert Review of Vaccines|May 11, 2013
What next for botulism vaccine development?Robert P Webb, Leonard A SmithAdvances in Preventive Medicine|April 27, 2012
The need for continued development of ricin countermeasuresRonald B Reisler, Leonard A SmithChaos (Woodbury, N.Y.)|July 30, 2024
The challenge of non-Markovian energy balance models in climateNicholas W Watkins, Raphael Calel, Sandra C Chapman, et al.Human Vaccines|August 18, 2009
Botulinum neurotoxin vaccines: Past history and recent developmentsJanice M Rusnak, Leonard A SmithCritical Reviews in Immunology|January 17, 2008
Botulinum neurotoxin vaccines: past, present, and futureLeonard A Smith, Janice M RusnakProtein Expression and Purification|November 22, 2005
Expression, purification, and characterization of Clostridium botulinum type B light chainJanice Gilsdorf, Nizamettin Gul, Leonard A SmithIEEE Transactions on Bio-Medical Engineering|May 29, 2003
Comparison of predictability of epileptic seizures by a linear and a nonlinear methodPatrick E McSharry, Leonard A Smith, Lionel TarassenkoBiochemistry|October 29, 2003
Autocatalytically fragmented light chain of botulinum a neurotoxin is enzymatically activeS Ashraf Ahmed, Peter McPhie, Leonard A SmithPlos One|September 30, 2010
Light chain separated from the rest of the type a botulinum neurotoxin molecule is the most catalytically active formNizamettin Gul, Leonard A Smith, S Ashraf AhmedPageof 10